To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Trial Details

NCT ID

NCT06352008

Phase

PHASE2

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Anlotinib

Locations (sample)

• Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

• The subjects voluntarily joined the study, signed the informed consent, and the compliance was good;
• ≥18 years old (calculated by the date of signing the informed consent); Both men and women; ECOG score 0\~1; Expected survival ≥3 months;
• Patients with stage IIA-IIIA NSCLC who had previously received PD-1/PD-L1 inhibitors combined with chemotherapy neoadjuvant therapy and underwent R…
• For patients who did not achieve pathological complete response after PD-1/PD-L1 inhibitor combined with chemotherapy neoadjuvant treatment, and th…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.